2025. Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s695. DOI:https://doi.org/10.25251/m10xva58.